BMY
Bristol-Myers Squibb
Pharmaceutical Preparations · Health Care
$61.71-2.08%
Quote via Yahoo Finance, may be delayed · 2026-11-03 · 4:00 PM ET
Daily prices: Yahoo Finance, split-adjusted. As of 2026-11-03.
Drag across the line to read a price. Dots mark earnings, filings and dividends.
Mixed profile
FCF yield lifts this profile the most.
As of 2025-12-31. Latest quarter ended 2026-09-30. v1 methodology, subject to change.
The profile score is 6 points higher since last quarter. Growth is 11 points higher. Momentum is 8 points higher.
Sector rank 8 of 46
In plain English
- Bristol-Myers Squibb operates in Pharmaceutical Preparations.
- Latest-year revenue was 48.2 billion.
- The profile score is 60, a Mixed profile. Price is the strongest listed input.
This company's filings do not tag an operating income line, and no total-costs figure exists to derive one. Operating margin, ROIC, margin stability, net debt to EBITDA, interest cover and Altman Z are left blank rather than estimated. Net income, revenue and cash flow come from the filing as reported.
Written from the figures on this page. No language model was called. It may still be wrong. Not advice.
As of 2025-12-31. Latest quarter ended 2026-09-30. SEC EDGAR companyfacts, fetched 2026-11-01. SEC filing
Financials
Tap a column to read the value.
P/E vs own history
Now 13.6 times, 5-year median 17.8 times.
Line is the quarterly multiple. The band is the 25th to 75th percentile of that history. The dashed line is the median.
Earnings
Actual earnings per share from EDGAR filings. Historical estimates are not used.
Actual from EDGAR
Data confidence
The Company Score summarises financial characteristics relative to similar companies using a published formula. It does not predict future returns.
SEC EDGAR companyfacts, fetched 2026-11-01.